Daily Blood Tests Could Shorten Antibiotic Courses in Sepsis

What the ADAPT-Sepsis Trial Evaluated

Daily procalcitonin (PCT) blood tests prompted intensive care doctors to consider stopping antibiotics nearly two days earlier than C-reactive protein (CRP) testing. Researchers from the University of Manchester and the Northern Care Alliance National Health Service (NHS) Foundation Trust published the process evaluation in the journal Anaesthesia.

The ADAPT-Sepsis trial tracked 2,760 patients across 41 adult intensive care units in the United Kingdom. Researchers analyzed more than 17,000 blood samples and treatment recommendations to assess automated daily stopping advice.

Comparing Procalcitonin to C-Reactive Protein

Procalcitonin levels generated stopping recommendations faster than traditional inflammation testing. Guidance based on procalcitonin signaled treatment cessation nearly two days ahead of C-reactive protein guidance.

Clinical teams responded differently to each blood marker. Doctors followed treatment advice linked to C-reactive protein more frequently because that marker closely mirrors current prescribing habits and standard treatment schedules.

Why Clinicians Overrode Early Stopping Advice

Doctors frequently chose to continue antibiotic therapy despite test recommendations to stop. Clinical teams cited several practical reasons during the trial when overriding automated treatment guidance.

• Existing microbiology guidelines that mandate fixed treatment durations
• Clinical concern regarding ongoing severe illness in the patient
• Persistent fever observed during the intensive care stay
• Elevated inflammation markers that remained above target levels

Clinical Relevance for Infection Management and Recovery

Sepsis occurs when the body mounts an overwhelming response to infection, leading to acute organ dysfunction. Patients often receive prolonged courses of broad-spectrum antibiotics because clinicians fear halting medication too early in critically ill individuals.

Prolonged antibiotic exposure drives antimicrobial resistance, increases clinical side effects, and raises hospital costs. Lead researcher Paul Dark noted that daily biomarker tracking offers an objective layer of reassurance for clinicians deciding when treatment has completed its job.